MétaCan
Menu
Back to cohort
Record W4414167244 · doi:10.1001/jamaneurol.2025.3373

Five-Year Outcomes from Deep Brain Stimulation of the Subthalamic Nucleus for Parkinson Disease

2025· article· en· W4414167244 on OpenAlexfundno aff
Philip A. Starr, Rajat S. Shivacharan, E. Matilda Goldberg, Alexander I. Tröster, P.A. House, Monique Giroux, Adam O. Hebb, Donald Whiting, Timothy Leichliter, Jill L. Ostrem, Leo Verhagen Metman, Sepehr Sani, Jessica Karl, Mustafa Siddiqui, Stephen B. Tatter, Ihtsham Haq, André G. Machado, Michał Gostkowski, Michele Tagliati, Adam N. Mamelak, Michael S. Okun, Kelly D. Foote, Guillermo Moguel‐Cobos, Francisco A. Ponce, Rajesh Pahwa, Kelly Lyons, Cathrin M. Buetefisch, Robert E. Gross, Corneliu Luca, Jonathan Jagid, Gonzalo J. Revuelta, István Takács, Michael Pourfar, Alon Y. Mogilner, Andrew P. Duker, George Mandybur, Joshua M. Rosenow, Cindy Zadikoff, Suketu M. Khandhar, Mark Sedrak, Fenna T. Phibbs, Joseph S. Neimat, Jennifer Durphy, Adolfo Ramirez‐Zamora, Julie G. Pilitsis, Ryan J. Uitti, Robert E. Wharen, Michael C. Park, Jerrold L. Vitek, Marta San Luciano, Nicholas B. Galifianakis, Lauren E. Schrock, Scott E. Cooper, Sierra Farris, Jules M. Nazzarro

Bibliographic record

VenueJAMA Neurology · 2025
Typearticle
Languageen
FieldMedicine
TopicNeurological disorders and treatments
Canadian institutionsnot available
FundersNational Institute of Neurological Disorders and StrokeLeonard M. Miller School of MedicineVanderbilt University Medical CenterUniversity of LouisvilleCedars-Sinai Medical CenterSchool of Medicine, Emory UniversityUniversity of MinnesotaUniversity of South CarolinaUniversity of CincinnatiCollege of Medicine, University of FloridaCleveland ClinicEmory UniversityKaiser PermanenteNorthwestern UniversityYork UniversityUniversity of MiamiVanderbilt University
KeywordsDeep brain stimulationSubthalamic nucleusDiseaseParkinson's diseaseMotor symptomsCentral nervous system diseaseClinical neurology

Abstract

fetched live from OpenAlex

Importance: The Implantable Neurostimulator for the Treatment of Parkinson's Disease (INTREPID) trial was a randomized, double-blind, sham-controlled study of subthalamic nucleus (STN) deep brain stimulation (DBS) for the treatment of Parkinson disease (PD). Objective: To evaluate the long-term (5-year) outcomes and safety of STN-DBS for PD. Design, Setting, and Participants: This was a prospective, randomized (3:1), 12-week double-blind sham-controlled study at 23 movement disorder centers across the US with an open-label 5-year follow-up. Patients were implanted and followed up with the Vercise DBS system from May 2013 to December 2022. Eligibility required diagnosis of bilateral idiopathic PD with more than 5 years of motor symptoms, more than 6 hours per day of poor motor function, modified Hoehn and Yahr Scale scores higher than 2, Unified Parkinson's Disease Rating Scale (UPDRS-III) score of 30 or higher (medication-off state), and 33% or higher improvement in UPDRS-III medication-on score. Intervention: Bilateral STN-DBS for moderate to advanced PD. Main Outcomes and Measures: Primary outcomes included changes in UPDRS and dyskinesia scores, quality-of-life measures, and safety assessments. Exploratory analyses included medication reduction and DBS association with motor signs. Results: A total of 313 patients were enrolled with 191 receiving the DBS system, and 137 participants (72%) completed the study. The study population had a mean (SD) age of 60 (7.9) years, with 139 (73%) male participants. Motor function without medication as measured by UPDRS-III improved from a mean (SD) of 42.8 (9.4) to 21.1 (10.6) at year 1 (51%; 95% CI, 49%-53%; P < .001) and 27.6 (11.6) at year 5 (36%; 95% CI, 33%-38%; P < .001). Activities of daily living without medication as measured by UPDRS-II improved from a mean (SD) of 20.6 (6.0) to 12.4 (6.1) at year 1 (41%; 95% CI, 38%-42%; P < .001) and 16.4 (6.5) at year 5 (22%; 95% CI, 18%-23%; P < .001). Dyskinesia scores decreased from 4.0 (5.1) to 1.0 (2.1) at year 1 (75%; 95% CI, 73%-75%; P < .001) and to 1.2 (2.1) at year 5 (70%; 95% CI, 63%-75%; P < .001). The levodopa equivalent dose was reduced by 28% at year 1, remaining stable at year 5 (28%; 95% CI, 26%-31%; P < .001). The most common serious adverse event was infection (9 participants). Ten deaths were reported, none related to the study. Conclusions and Relevance: Although STN-DBS outcomes declined slightly, possibly due to the progressive nature of the disease, patients with PD sustained significant improvement in motor and activities of daily living scores, along with a stable reduction in anti-parkinsonian medication over the 5-year follow-up period.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.001
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.021
Threshold uncertainty score0.268

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0000.001
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.014
GPT teacher head0.275
Teacher spread0.261 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations16
Published2025
Admission routes1
Has abstractyes

Explore more

Same venueJAMA NeurologySame topicNeurological disorders and treatmentsFrench-language works237,207